REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Voluntary delisting from the NASDAQ Capital Market

10 Dec 2019 07:00

RNS Number : 2765W
Motif Bio PLC
10 December 2019
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

Confirmation of timing of voluntary delisting from the NASDAQ Capital Market

 

Motif Bio plc (AIM/Nasdaq: MTFB) announces that in furtherance of the previously announced voluntary de-listing from the NASDAQ Capital Market for the Company's American Depository Shares (ADS's), the Company has filed Form 25 with the US Securities and Exchange Commission on the 9 December 2019. The Company expects that the last trading day on the NASDAQ Capital Market will be on or about 16 December 2019 as previously announced in the RNS issued on the 26 November 2019.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

 

For further information please contact:

 

 

Motif Bio plc

ir@motifbio.com

Graham Lumsden (Chief Executive Officer)

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0)20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Abigail Wayne (Sales & Broking)

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/Lianne Cawthorne

motifbio@walbrookpr.com

MC Services AG (EUROPEAN IR)

+49 (0)89 210 2280

Raimund Gabriel

raimund.gabriel@mc-services.eu

 

 

Forward-Looking Statements

When used in this Press Release, the words or phrases "intends," "anticipates," "expected to be" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties including, but not limited to, changes in economic conditions in the Company's market area, changes in policies by regulatory agencies, fluctuations in interest rates, competition that could cause actual results to differ materially from historical earnings and those presently anticipated or projected, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company advises readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revision which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFSSESUFUSELE
Date   Source Headline
8th Jun 20172:32 pmRNSHolding(s) in Company
5th Jun 20176:20 pmRNSPublication of Shareholder Circular
2nd Jun 20174:36 pmRNSResult of Placing
2nd Jun 20177:00 amRNSProposed Placing
23rd May 20174:40 pmRNSSecond Price Monitoring Extn
23rd May 20174:35 pmRNSPrice Monitoring Extension
18th May 20177:00 amRNSPublication of UK Annual Report and Accounts
10th May 20177:00 amRNSAppointments to Scientific Advisory Board
5th May 20177:00 amRNSDirectorate Change
2nd May 20173:10 pmRNSExercise of Warrants and Issue of Equity
2nd May 20177:00 amRNSAnnual Financial Report
28th Apr 201712:00 pmRNSChange of Adviser
24th Apr 20177:00 amRNSNotification of change in holding of shareholder
18th Apr 20177:00 amRNSPositive Data Readout for Iclaprim Phase 3 Trial
12th Apr 20173:06 pmRNSHolding(s) in Company
12th Apr 20173:01 pmRNSHolding(s) in Company
31st Mar 20174:15 pmRNSChange of Registered Office
8th Feb 20172:57 pmRNSInvestor Presentation
8th Feb 20177:00 amRNSDirector/PDMR Shareholding
7th Feb 20177:02 amRNSDirector/PDMR Shareholding
31st Jan 20173:36 pmRNSHardman Research: Further de-risking of iclaprim
31st Jan 20177:00 amRNSClinical trial finishes patient treatment phase
27th Jan 20176:13 pmRNSHolding(s) in Company
18th Jan 20177:05 amRNSDirector/PDMR Shareholding
18th Jan 20177:00 amRNSAppointment of Chief Financial Officer
9th Jan 20175:28 pmRNSIssue of Equity
3rd Jan 201712:31 pmRNSHolding(s) in Company
30th Dec 20163:09 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
21st Dec 20165:50 pmRNSConversion of CPNs, PDMR Dealing & TVR
21st Dec 20164:17 pmRNSIssue of Equity & Total Voting Rights
21st Dec 20163:05 pmRNSResult of GM
19th Dec 20165:58 pmRNSHolding(s) in Company
8th Dec 20167:45 amRNSHolding(s) in Company
5th Dec 20167:00 amRNSPublication of circular and notice of GM
1st Dec 20165:27 pmRNSIssue of Equity
25th Nov 201611:32 amRNSHolding(s) in Company
24th Nov 20161:36 pmRNSHolding(s) in Company
23rd Nov 20165:12 pmRNSHolding(s) in Company
23rd Nov 20164:56 pmRNSClosing of public offer
18th Nov 201612:51 pmRNSConfirms successful European placing
18th Nov 20167:16 amRNSUS Pricing and European Placing to raise US$25m
4th Nov 20161:34 pmRNSHolding(s) in Company
4th Nov 20161:20 pmRNSHolding(s) in Company
31st Oct 20167:00 amRNSUpdate on US Public Offering
31st Oct 20167:00 amRNSNew Data on Iclaprim
31st Oct 20167:00 amRNSData Confirming Standard Clinical Trial Dosage
16th Sep 20164:40 pmRNSSecond Price Monitoring Extn
16th Sep 20164:35 pmRNSPrice Monitoring Extension
15th Sep 20167:00 amRNSPosters presented at IDWeek New Orleans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.